The global retinal vein occlusion market size was valued at USD 2.77 billion in 2025 and is projected to grow from USD 2.95 billion in 2026 to USD 4.85 billion by 2034, registering a CAGR of 6.41% during the forecast period from 2026 to 2034. North America dominated the retinal vein occlusion market with a market share of 39.5% in 2025.
The retinal vein occlusion includes diagnostic tools, medications, and treatment solutions used to manage blockage of the retinal veins, which can cause vision loss, swelling, and retinal damage. The market covers anti-VEGF drugs, corticosteroids, laser therapy, and imaging technologies. Growth is supported by the rising prevalence of diabetes, hypertension, and age-related eye disorders, along with improved retinal screening and treatment access.
Download a Free Sample To learn more about this report,
Increasing Adoption of Longer-Acting Therapies for Retinal Vein Occlusion
The retinal vein occlusion market is increasingly focused on therapeutic approaches designed to reduce treatment burden by extending the duration of disease control between interventions. Longer-acting anti-VEGF therapies and sustained treatment strategies are becoming important areas of clinical and pharmaceutical development, particularly for patients requiring repeated management of macular edema associated with retinal vein occlusion.
In February 2025, ophthalmology companies continued advancing treatment approaches focused on improving durability and reducing the frequency of interventions required for chronic retinal disease management.
Growing Use of Advanced Retinal Imaging and Diagnostic Technologies
Healthcare providers are increasingly using advanced retinal imaging technologies to support the diagnosis, monitoring, and management of retinal vein occlusion. Optical coherence tomography and other imaging approaches help specialists evaluate retinal changes and monitor treatment response over time. Continued improvements in imaging capabilities are supporting more detailed assessment and management of retinal disorders.
In July 2025, ophthalmology providers continued expanding the use of advanced retinal imaging technologies to support the diagnosis and ongoing monitoring of retinal diseases.
Growing Prevalence of Age-Related and Cardiovascular Risk Factors
Retinal vein occlusion is associated with several systemic and ocular risk factors, including increasing age and cardiovascular conditions. The growing prevalence of hypertension, diabetes, and other vascular health conditions contributes to the expanding population at risk of retinal vascular disorders. Increasing demand for ophthalmic diagnosis and treatment is therefore supporting the retinal vein occlusion market.
In April 2025, healthcare organizations continued emphasizing the relationship between cardiovascular health, aging, and the growing burden of vascular-related health conditions.
High Cost of Long-Term Ophthalmic Treatment
The management of retinal vein occlusion can involve repeated specialist consultations, diagnostic imaging, and ongoing therapeutic interventions. For patients requiring frequent intravitreal treatment, cumulative healthcare costs can become substantial. Limited reimbursement coverage and affordability constraints can therefore restrict access to certain advanced retinal therapies.
In June 2025, healthcare providers and payers continued managing the financial burden associated with long-term treatment and monitoring of chronic retinal diseases.
Expansion of Specialized Retinal Care Services in Emerging Markets
Growing investment in ophthalmology infrastructure and specialized retinal care services is creating opportunities for improved diagnosis and treatment of retinal vein occlusion in emerging healthcare markets. Expanding access to retinal specialists, diagnostic imaging, and modern treatment options can enable a greater number of patients to receive appropriate care. This development represents an important growth opportunity for pharmaceutical companies and ophthalmic service providers.
In September 2025, healthcare development initiatives continued supporting the expansion of specialized ophthalmology and retinal care capabilities across developing healthcare markets.
Maintaining Patient Adherence to Repeated Treatment and Follow-Up
Many patients with retinal vein occlusion require regular monitoring and, in some cases, repeated treatment over extended periods. Frequent clinical visits can create logistical and financial challenges, particularly for older patients and individuals with limited access to specialized retinal centers. Maintaining adherence to recommended treatment and follow-up schedules therefore remains a significant challenge in achieving effective long-term disease management.
In November 2025, retinal care programs continued emphasizing the importance of consistent monitoring and follow-up for patients receiving long-term treatment for retinal diseases.
Branch Retinal Vein Occlusion (BRVO) Dominated the Market with 57.3% Share in 2025
The Branch Retinal Vein Occlusion (BRVO) segment accounted for the largest share of the global Retinal Vein Occlusion Market at 57.3% in 2025, driven by its higher incidence compared to central retinal vein occlusion and increasing diagnosis through advanced retinal imaging technologies. Growing awareness of vision-related disorders, rising prevalence of hypertension and diabetes, and improved access to ophthalmic care continue to strengthen the segment's market leadership.
Request Customizationto receive a tailored report.
Anti-vascular Endothelial Growth Factor (Anti-VEGF) is Projected to Register the Fastest Growth at a CAGR of 6.91%
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) segment is expected to expand at the fastest CAGR of 6.91% during 2026–2034, supported by its proven effectiveness in reducing macular edema and improving visual outcomes in retinal vein occlusion patients. Increasing adoption of targeted biologic therapies, growing availability of long-acting anti-VEGF formulations, and continuous advancements in retinal disease management are expected to accelerate segment growth.
Hospital Pharmacies Dominated the Market with 54.8% Share in 2025
The Hospital Pharmacies segment held the largest market share of 54.8% in 2025, owing to the high volume of intravitreal injections and specialized retinal treatments administered in hospital settings. The availability of ophthalmology specialists, advanced diagnostic equipment, and comprehensive patient care services, along with efficient management of prescription biologics, continues to reinforce the segment's dominant position.
Speak to an Analystto discuss market opportunities.
Asia Pacific accounted for 22.6% of the retinal vein occlusion market, reaching USD 0.63 billion in 2025. The region is projected to register the fastest growth at a CAGR of 7.35% during the forecast period. Growth is driven by the rapidly aging population, rising prevalence of diabetes and hypertension, increasing incidence of retinal vascular disorders, and expanding access to advanced ophthalmology care. Growing adoption of optical coherence tomography (OCT) imaging and anti-VEGF therapies continues to support regional market expansion.
China accounted for an estimated USD 0.27 billion in 2025, making it the largest market in Asia Pacific. Growth is supported by a large diabetic population, expanding ophthalmology hospitals, increasing government healthcare investments, and rising adoption of advanced retinal imaging and anti-VEGF therapies.
Japan generated an estimated USD 0.15 billion in 2025. The country's aging population, advanced ophthalmic healthcare infrastructure, high utilization of innovative retinal therapies, and increasing diagnosis of retinal vascular diseases continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
North America dominated the retinal vein occlusion market with a 39.5% market share, valued at USD 1.09 billion in 2025. The region benefits from advanced ophthalmology infrastructure, high adoption of anti-VEGF therapies, favorable reimbursement policies, and strong clinical research activities. Increasing prevalence of retinal disorders among the elderly population and continuous introduction of innovative retinal treatments continue to drive regional market growth.
The United States accounted for an estimated USD 0.90 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by widespread use of anti-VEGF injections, strong clinical research, increasing diagnosis through advanced retinal imaging technologies, and the presence of leading pharmaceutical companies.
Canada generated an estimated USD 0.13 billion in 2025. Rising healthcare expenditure, expanding access to retinal specialists, increasing use of OCT imaging, and growing adoption of innovative ophthalmic therapies continue to support market expansion.
Europe accounted for 28.4% of the retinal vein occlusion market, reaching USD 0.79 billion in 2025. The market is supported by well-established ophthalmology care systems, favorable reimbursement policies, increasing investments in retinal disease management, and growing adoption of advanced diagnostic technologies. Rising awareness of vision-threatening retinal disorders continues to contribute to regional growth.
Germany led the European market with an estimated value of USD 0.23 billion in 2025. The country's advanced ophthalmology infrastructure, increasing clinical research, widespread availability of retinal imaging technologies, and high healthcare expenditure continue to drive market growth.
The United Kingdom represented an estimated USD 0.14 billion in 2025. Growth is driven by NHS-supported retinal treatment programs, expanding access to anti-VEGF therapies, increasing adoption of OCT imaging, and rising diagnosis of retinal vascular disorders.
Latin America accounted for 5.4% of the Retinal Vein Occlusion Market, reaching USD 0.15 billion in 2025. Rising healthcare expenditure, expanding ophthalmology services, improving access to retinal specialists, and increasing awareness of retinal vascular diseases are supporting regional market growth.
Brazil accounted for an estimated USD 0.08 billion in 2025, making it the largest market in Latin America. Increasing investments in ophthalmology infrastructure, expanding private eye care facilities, and growing adoption of advanced retinal therapies continue to support market expansion.
The Middle East & Africa represented 4.1% of the retinal vein occlusion market, totaling USD 0.11 billion in 2025. Increasing investments in ophthalmology infrastructure, improving access to specialized eye care, growing awareness of retinal diseases, and government initiatives to reduce vision impairment are supporting regional market growth.
The United Arab Emirates (UAE) accounted for an estimated USD 0.03 billion in 2025. The country's market is driven by investments in advanced eye care centers, expanding medical tourism, increasing adoption of retinal imaging technologies, and growing availability of innovative retinal therapies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Acne Treatment Market Size, Share & Growth Graph by 2034
Aesthetic Medicine Market Size, Share, Growth, Analysis, 2034
Anti-Osteoporosis Therapy and Fracture Healing Market Size, 2034
United Arab Emirates Influenza Treatment Market Size, 2034
North America Multiple Electrolytes Injection Market Size by 2034
North America Tulathromycin Market Size & Trends By 2034
We are featured on:
sales@straitsresearch.com